Last updated: August 27, 2026
RITUXAN, marketed as MabThera outside the United States, is a mature anti-CD20 biologic facing sustained revenue erosion from biosimilars, therapeutic substitution, and migration to newer Roche products. Roche's original rituximab franchise remains commercially relevant in oncology and autoimmune disease, but its strategic value is now concentrated in cash generation, lifecycle management, and combination use rather than growth.
Roche reported approximately CHF 1.2 billion in 2024 sales for the MabThera/Rituxan franchise, compared with multibillion-franc peak sales before biosimilar entry. The principal US biosimilars are Truxima, Ruxience, and Riabni. US regulatory exclusivity has ended, the key composition-of-matter patent position has expired, and commercial barriers now depend more on contracting, physician adoption, interchangeability, supply, and indication-specific reimbursement than on blocking patents.
What is RITUXAN and how large is its commercial market?
RITUXAN is rituximab, a chimeric monoclonal antibody that binds the CD20 antigen on B cells. Genentech commercializes RITUXAN in the United States, while Roche markets MabThera in many international markets. Biogen and Genentech jointly developed the product, with Roche holding the principal commercial rights.
The product received its first FDA approval in 1997 for relapsed or refractory low-grade or follicular B-cell non-Hodgkin lymphoma. Its approved and established uses include:
- Non-Hodgkin lymphoma
- Chronic lymphocytic leukemia
- Rheumatoid arthritis
- Granulomatosis with polyangiitis
- Microscopic polyangiitis
- Pemphigus vulgaris
- Selected combination regimens with chemotherapy
RITUXAN is administered intravenously. Its commercial market includes both oncology and immunology, but oncology has historically generated the largest revenue base.
RITUXAN commercial profile
| Metric |
Position |
| Active ingredient |
Rituximab |
| Originator |
Roche/Genentech |
| US brand |
RITUXAN |
| Major ex-US brand |
MabThera |
| FDA first approval |
1997 |
| Primary therapeutic class |
Anti-CD20 monoclonal antibody |
| Administration |
Intravenous infusion |
| Principal competitors |
Truxima, Ruxience, Riabni, biosimilar rituximab products |
| Major therapeutic substitutes |
Gazyva, Ocrevus, Kesimpta, Brukinsa, Calquence, disease-specific immunotherapies |
| Patent status |
Core exclusivity expired; no longer protected by an effective blocking composition patent |
| Commercial phase |
Mature, declining franchise |
The product's installed clinical base remains large. Hospitals and oncology practices have extensive experience with rituximab, and its lower price relative to newer anti-CD20 products supports continued use. Biosimilars have accelerated price competition but also expanded access in some settings.
How has RITUXAN revenue changed over time?
RITUXAN sales increased rapidly after expansion from lymphoma into rheumatoid arthritis, leukemia, and other autoimmune indications. The franchise reached peak commercial performance before the launch of multiple biosimilars and before Roche's newer products displaced some clinical demand.
Roche's reported MabThera/Rituxan sales have contracted to approximately CHF 1.2 billion annually. Roche reports currency effects and regional performance separately, so year-over-year comparisons should use the company's reported currency rather than convert figures into US dollars without adjustment.
Financial trajectory
| Period |
Market condition |
Financial effect |
| 1997-2005 |
Initial lymphoma expansion and label growth |
Rapid revenue growth |
| 2006-2013 |
Broader oncology and autoimmune use |
Peak franchise economics |
| 2014-2018 |
Patent expiry planning and biosimilar preparation |
Early pricing and competitive pressure |
| 2019-2020 |
First US and European biosimilars |
Accelerating price and share erosion |
| 2021-2022 |
Multiple biosimilars and contracting competition |
Lower net sales and margin pressure |
| 2023-2024 |
Mature biosimilar market |
Stable residual demand with declining originator revenue |
| 2025 onward |
Further price compression and product substitution |
Continued erosion, moderated by clinical familiarity and supply reliability |
RITUXAN's financial decline has been structural rather than cyclical. Three forces drive the trajectory:
- Biosimilar substitution reduces average selling prices and originator volume.
- Roche's Ocrevus and Gazyva capture selected patients and indications.
- Payers and providers increasingly use formulary position and acquisition cost to determine product selection.
Roche has partly offset RITUXAN erosion with newer medicines. Ocrevus, which targets CD20 in multiple sclerosis, has become one of Roche's largest products. Gazyva, or obinutuzumab, provides a next-generation anti-CD20 option in selected hematologic indications. This internal portfolio shift reduces Roche's dependence on rituximab revenue.
Which companies are challenging RITUXAN with biosimilars?
Three principal rituximab biosimilars have FDA approval for US use:
| Product |
Sponsor |
FDA approval |
Commercial significance |
| Truxima |
Celltrion |
November 2019 |
First US rituximab biosimilar; established early market position |
| Ruxience |
Pfizer |
July 2020 |
Broad commercial and hospital-channel competitor |
| Riabni |
Amgen and Allergan, now within Amgen's portfolio |
December 2020 |
Expanded competition across oncology and autoimmune channels |
These products were approved under the FDA's biosimilar pathway based on analytical, pharmacokinetic, pharmacodynamic, and clinical comparability evidence. Rituximab biosimilars are not interchangeable with RITUXAN under the FDA's automatic pharmacy-substitution standard unless separately designated interchangeable. Hospital and physician-administered products are often selected through institutional protocols, payer contracts, and buy-and-bill economics rather than retail substitution.
How strong is biosimilar penetration?
Biosimilar penetration is highest where:
- Hospitals operate centralized purchasing systems.
- Oncology treatment protocols permit product substitution.
- Payers impose preferred-product policies.
- The product is reimbursed under a buy-and-bill framework.
- Physicians have substantial experience with the biosimilar.
Penetration is less uniform in autoimmune indications because treatment continuity, payer authorization, infusion-center policy, and physician preference can slow switching. The market has nevertheless moved from a brand-dominated model to a multi-supplier model.
In Europe, rituximab biosimilar competition began earlier and is generally more established. Pricing varies by country because national tenders and reimbursement systems determine net prices. In the United States, launch sequencing, contracting, provider economics, and rebate structures produce substantial differences between list-price and net-price erosion.
When did RITUXAN lose exclusivity?
RITUXAN no longer has effective US regulatory or patent exclusivity capable of preventing biosimilar competition.
The FDA approved the originator before the modern Biologics Price Competition and Innovation Act framework. Rituximab therefore did not receive the 12-year reference-product exclusivity available to newer biologics approved under the Public Health Service Act framework. Its commercial protection depended primarily on patent rights, regulatory barriers, clinical adoption, and manufacturing scale.
The practical exclusivity timeline was:
| Event |
Date |
| First FDA approval |
1997 |
| Core US patent protection |
Expired before or around the initial US biosimilar launch period |
| First US rituximab biosimilar approval |
2019 |
| Multiple US biosimilars available |
2020 onward |
| Current status |
Open biosimilar competition |
Patent-term adjustments, pediatric extensions, formulation claims, and indication-specific claims can produce different expiration dates for individual patents. Those rights did not preserve a market-wide block against FDA-approved rituximab biosimilars.
What patents protect RITUXAN today?
The principal patent barriers for RITUXAN have expired or are no longer sufficient to prevent biosimilar commercialization. The historical patent estate covered several categories:
- Anti-CD20 antibodies and antibody sequences
- Antibody production and purification
- Treatment of B-cell malignancies
- Autoimmune-disease treatment methods
- Dosing regimens and combination therapies
- Liquid and concentrated antibody formulations
Are formulation patents still commercially important?
Formulation patents can remain relevant after composition patents expire, but their practical value depends on whether a competing biosimilar uses the claimed formulation and whether the patent is listed, asserted, or enforceable against that product.
For RITUXAN, formulation and process claims have not created a durable commercial barrier comparable to the original antibody patents. Biosimilar manufacturers can often design around formulation claims or rely on distinct manufacturing processes while satisfying FDA comparability requirements.
Manufacturing know-how remains more important than patent exclusivity. Rituximab requires control of cell culture, purification, viral clearance, aggregation, glycosylation, sterility, and cold-chain handling. These requirements create operational barriers, but they are not equivalent to legal exclusivity.
What is the Orange Book status of RITUXAN?
The Orange Book is not the principal patent database for biologic reference products. FDA biologics are generally governed through the Purple Book and the Public Health Service Act rather than the small-molecule Hatch-Waxman Orange Book framework.
For RITUXAN, the relevant legal framework is:
- Biologics License Application regulation
- Purple Book reference-product and biosimilar listings
- Patent litigation under the BPCIA
- Patent-law claims involving composition, formulation, manufacturing, and methods of use
This distinction affects litigation strategy. A rituximab biosimilar sponsor does not follow the same abbreviated new drug application and Orange Book Paragraph IV process used for a small-molecule generic.
Have RITUXAN biosimilars faced Paragraph IV challenges?
RITUXAN biosimilar challenges are not conventional Paragraph IV challenges. Paragraph IV certifications apply to abbreviated new drug applications under the Hatch-Waxman Act. Rituximab biosimilars use the BPCIA framework.
BPCIA disputes can involve:
- Patent-list exchanges between the biosimilar applicant and reference-product sponsor
- Patent disclosure and negotiation
- Declaratory-judgment actions
- Infringement litigation over disclosed or later-asserted patents
- Commercial-launch agreements
- Injunction and damages claims
The US rituximab biosimilar market developed without a continuing patent injunction that prevented all three major products from entering. The commercial disputes were therefore less important than the product-level economics of contracting, supply, physician adoption, and reimbursement.
What patent litigation and settlement agreements affect RITUXAN?
The relevant litigation risk has shifted from blocking market entry to managing individual patent claims, launch timing, and commercial terms. Roche and its affiliates have historically used patent litigation, regulatory strategy, and commercial negotiations to protect biologic franchises. For rituximab, biosimilar launches proceeded after the originator's principal exclusivity period, demonstrating that the remaining estate did not sustain a broad exclusionary position.
Settlement agreements can govern:
- Earliest commercial launch dates
- Product-specific launch conditions
- Patent claims surrendered or preserved
- Manufacturing and supply arrangements
- Damages and release provisions
The financial importance of any settlement is now lower than it would have been before 2019 because multiple competitors are already present. A settlement with one biosimilar sponsor does not remove competitive pressure from other suppliers.
How does RITUXAN compare with Ocrevus and Gazyva?
RITUXAN remains the lower-cost, high-volume anti-CD20 reference product. Ocrevus and Gazyva have stronger growth and exclusivity profiles but address different clinical segments.
| Product |
Active ingredient |
Primary position |
Competitive status |
| RITUXAN/MabThera |
Rituximab |
Mature oncology and autoimmune franchise |
Multiple biosimilars |
| Gazyva/Gazyvaro |
Obinutuzumab |
Selected hematologic malignancies and lupus development |
Patent-protected branded product |
| Ocrevus |
Ocrelizumab |
Multiple sclerosis |
High-growth Roche franchise |
| Kesimpta |
Ofatumumab |
Multiple sclerosis, subcutaneous administration |
Novartis competitor |
| Arzerra legacy franchise |
Ofatumumab |
Earlier CD20 product |
Limited commercial relevance |
RITUXAN retains advantages in clinical familiarity, broad labeling, physician experience, and accumulated safety data. It lacks the exclusivity, delivery differentiation, and growth profile of newer products.
What generic entry risks exist for RITUXAN?
Traditional generic entry is not the relevant risk. The principal risk is biosimilar erosion.
Near-term risks
- Further discounts from Celltrion, Pfizer, and Amgen
- Greater payer preference for biosimilars
- Hospital conversion from originator to lowest-cost supplier
- Reduced use of RITUXAN in newly diagnosed patients
- More aggressive tendering in Europe
- Use of obinutuzumab or other anti-CD20 products in selected indications
Residual protections
- Physician and patient familiarity
- Established infusion protocols
- Supply reliability
- Contracting relationships
- Clinical comfort in autoimmune disease
- Potential differences in payer coverage and authorization
- Brand preference in narrow treatment settings
The most likely commercial scenario is continued gradual originator decline rather than abrupt zero-revenue displacement. RITUXAN can remain profitable at lower volume because the product has an established manufacturing base and limited need for large new clinical investment.
What licensing deals support the RITUXAN franchise?
RITUXAN originated from collaboration between IDEC Pharmaceuticals and Genentech, later integrated into Roche's global pharmaceutical structure. The commercial model included regional rights, development collaboration, and Roche's subsequent ownership of Genentech.
The principal strategic licensing issue today is not a new RITUXAN licensing deal. It is Roche's ability to replace rituximab revenue through internally controlled products such as Ocrevus and Gazyva. Biosimilar sponsors rely on their own development and manufacturing capabilities, although commercial partnerships and regional distribution arrangements can affect market access.
What is RITUXAN's FDA regulatory status?
RITUXAN has full FDA approval across multiple oncology and autoimmune indications. It is not an investigational product, and its principal regulatory risk is not approval withdrawal. The relevant FDA issues are:
- Biosimilar labeling and indication extrapolation
- Infusion-related reaction management
- Progressive multifocal leukoencephalopathy warnings
- Hepatitis B reactivation monitoring
- Immunosuppression and infection risk
- Pediatric and special-population labeling
- Manufacturing consistency and supply
Biosimilar approvals may include indications supported through extrapolation rather than separate full clinical trials in every disease area. FDA approval does not automatically establish interchangeability or guarantee substitution in every payer channel.
How strong is the RITUXAN patent estate?
RITUXAN's current patent estate is weak as a market-exclusion tool and moderate as a litigation and negotiation asset.
| Patent-estate factor |
Assessment |
| Core antibody protection |
Expired or commercially ineffective |
| Formulation protection |
Limited residual leverage |
| Method-of-use claims |
Potentially relevant for narrow indications |
| Manufacturing claims |
Operationally relevant but generally design-aroundable |
| Regulatory exclusivity |
Expired |
| Biosimilar blocking power |
Low |
| Brand and clinical familiarity |
High |
| Supply-chain advantage |
Moderate |
| Long-term growth potential |
Low |
The product's competitive moat is now operational and clinical rather than primarily legal.
What is the outlook for RITUXAN revenue and market share?
RITUXAN revenue should continue to decline over the medium term, with the pace determined by biosimilar contracting and Roche's ability to retain premium positioning in autoimmune disease and selected oncology protocols.
The likely financial pattern is:
- Lower global net price
- Declining originator share
- Continued unit demand across lymphoma and autoimmune disease
- Stable but smaller cash contribution
- Greater exposure to hospital tenders and payer formulary decisions
- Minimal benefit from new label expansion compared with earlier years
Roche's broader anti-CD20 portfolio reduces the strategic importance of RITUXAN revenue. The company can accept lower rituximab sales if patients migrate to higher-value products such as Ocrevus or Gazyva. For biosimilar manufacturers, the market remains attractive because rituximab has high clinical utilization, established reimbursement pathways, and a large installed treatment base.
Key Takeaways
- RITUXAN is a mature Roche biologic with approximately CHF 1.2 billion in recent annual MabThera/Rituxan sales.
- Core exclusivity has expired, and three major US biosimilars compete directly.
- Truxima launched first in the United States in 2019, followed by Ruxience and Riabni in 2020.
- The relevant US pathway is the BPCIA, not a traditional Hatch-Waxman Paragraph IV process.
- Patent protection is no longer capable of broadly blocking rituximab biosimilar entry.
- Formulation, manufacturing, and method-of-use claims have limited residual commercial leverage.
- Revenue erosion will continue, but the franchise should retain residual value because of clinical familiarity, broad use, and established supply infrastructure.
- Roche's principal defense is portfolio migration toward Ocrevus and Gazyva rather than preservation of RITUXAN's former monopoly.
FAQs
Is RITUXAN still profitable after biosimilar entry?
Yes. Lower net prices and volume share have reduced revenue, but established manufacturing, clinical demand, and limited incremental development costs can support continued profitability.
Which RITUXAN biosimilar has the strongest US position?
Truxima has the first-mover advantage, while Ruxience and Riabni benefit from large pharmaceutical-company commercial infrastructure. Relative strength varies by payer, hospital system, and indication.
Can a pharmacy automatically substitute a RITUXAN biosimilar?
Not automatically in every case. FDA biosimilarity does not equal interchangeability. Hospital protocols, payer rules, physician orders, and state law determine practical substitution.
Does RITUXAN compete directly with Ocrevus?
Only partly. Both target CD20-positive B-cell biology, but Ocrevus is primarily positioned in multiple sclerosis, while RITUXAN is concentrated in lymphoma, leukemia, and autoimmune diseases.
Will RITUXAN sales reach zero?
A complete collapse is unlikely in the near term. The product has a broad clinical base and may retain demand in indications where physicians, payers, or health systems value its established use and lower cost.
References
-
Genentech. (2024). RITUXAN (rituximab) prescribing information. U.S. Food and Drug Administration.
-
Roche Holding AG. (2025). Annual report 2024. Basel, Switzerland: Roche.
-
U.S. Food and Drug Administration. (2019). FDA approves first biosimilar to rituximab. Silver Spring, MD: FDA.
-
U.S. Food and Drug Administration. (2020a). FDA approves biosimilar to Rituxan. Silver Spring, MD: FDA.
-
U.S. Food and Drug Administration. (2020b). FDA approves biosimilar to Rituxan for non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis. Silver Spring, MD: FDA.
-
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. Silver Spring, MD: FDA.
-
U.S. Congress. (2010). Patient Protection and Affordable Care Act, Biologics Price Competition and Innovation Act of 2009. Washington, DC: U.S. Government Publishing Office.
-
European Medicines Agency. (2024). MabThera: EPAR product information. Amsterdam, Netherlands: EMA.
